DE SANGOSSE ACQUIRES FINE HOLDINGS LIMITED
The DE SANGOSSE group announces the acquisition of Fine Holdings Limited and its wholly-owned subsidiaries, Fine Agrochemicals Limited and Fine Americas, Inc, strengthening its strategy of international development.
Fine is a global market leader specialising in the development and marketing of plant growth regulators (PGRs) targeted primarily in the niche fruit and ornamental sectors. The acquisition represents a new strategic core business area for DE SANGOSSE.
“This acquisition strengthens our leading position in specialty markets at the world level " specifies Nicolas Fillon, CEO of the DE SANGOSSE group who adds " Fine, with its 150 registrations and its presence in more than 40 countries will allow us to accelerate the international development of the group’s business. "
From Fine’s perspective, the group will benefit from the additional resources of DE SANGOSSE to pursue and increase the pace of new product development, support its brands and strengthen its partnerships in the numerous countries where it is present.
For Fine, Julian Ward - Managing Director, "the purchase of Fine by DE SANGOSSE is an opportunity to strengthen and accelerate the development of our new projects and benefit from DE SANGOSSE’s resources. We do indeed share the same philosophy, the selective approach to the markets and the integration of the product development chain including research, formulation, registration and marketing."
In a growing global crop protection world market, the obvious synergies
of this acquisition are consistent with the ambitions of the group DE SANGOSSE.
The Fine group (Worcester - UK) is a global market leader specialising in the development and marketing of plant growth regulators targeted primarily in the niche fruit and ornamental sectors. Established in 1994 and with operations based in both the UK and the US, Fine serves a global client base and is run by a highly experienced and successful management team who has consistently reached key milestones and exceeded revenue and profitability levels for many years in succession. Fine has developed an extensive product portfolio of PGRs and is now a world leader in the market sectors in which it operates. It is Fine’s philosophy to build equity into its products by having maximum control over all aspects including manufacture, formulation, registration and intellectual property. Fine not only invests in research to maintain and extend the use of its existing products but is investing heavily in developing new molecules. This will enable it to enter new market sectors that are significantly larger than its traditional markets. Led by its management team, the Group is supported by a loyal and highly qualified work force.